Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.
Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, Lombardi F, Emiliozzi A, Belmonti S, Antinori A, Cauda R, Di Giambenedetto S. Borghetti A, et al. Among authors: baldin g. HIV Med. 2019 Oct;20(9):624-627. doi: 10.1111/hiv.12759. Epub 2019 Jun 25. HIV Med. 2019. PMID: 31240860 Free article.
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication.
Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Latini A, Cossu MV, Gagliardini R, De Luca A, Di Giambenedetto S. Borghetti A, et al. Among authors: baldin g. HIV Med. 2018 Mar 24. doi: 10.1111/hiv.12611. Online ahead of print. HIV Med. 2018. PMID: 29573320 Free article.
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G, Ciccullo A, Capetti A, Rusconi S, Sterrantino G, Cossu MV, Giacomelli A, Lagi F, Latini A, Bagella P, De Luca A, Di Giambenedetto S, Madeddu G. Baldin G, et al. HIV Med. 2019 Feb;20(2):164-168. doi: 10.1111/hiv.12688. Epub 2018 Nov 20. HIV Med. 2019. PMID: 30457197 Free article.
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S. Borghetti A, et al. Among authors: baldin g. J Antimicrob Chemother. 2016 Aug;71(8):2359-61. doi: 10.1093/jac/dkw147. Epub 2016 May 4. J Antimicrob Chemother. 2016. PMID: 27147306 No abstract available.
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
Ciccullo A, Baldin G, Borghi V, Cossu MV, Giacomelli A, Lagi F, Farinacci D, Iannone V, Passerotto RA, Capetti A, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S. Ciccullo A, et al. Among authors: baldin g. J Antimicrob Chemother. 2022 Dec 23;78(1):117-121. doi: 10.1093/jac/dkac362. J Antimicrob Chemother. 2022. PMID: 36272137
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F, Baldin G, Colafigli M, Capetti A, Madeddu G, Kiros ST, Di Giambenedetto S, Sterrantino G. Lagi F, et al. Among authors: baldin g. Int J Antimicrob Agents. 2019 Oct;54(4):487-490. doi: 10.1016/j.ijantimicag.2019.06.003. Epub 2019 Jun 11. Int J Antimicrob Agents. 2019. PMID: 31195121
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, Baldin GM, Soria A, Riccardi N, Niero FP, Celesia BM, Barbarini G, Rusconi S, Rizzardini G. Capetti AF, et al. Among authors: baldin gm. HIV Clin Trials. 2018 Dec;19(6):242-248. doi: 10.1080/15284336.2018.1550290. HIV Clin Trials. 2018. PMID: 30890064 Clinical Trial.
93 results